RxDoctor Payments Data

Aarti Campo, MD

Cardiovascular Disease · Poughkeepsie, NYNPI 1710189949

Payments from drug & device makers

$825in general payments, 2019–2025

Across 37 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$222
  • Astellas Pharma US Inc$198
  • Amgen$122
  • Boston Scientific$73
  • AstraZeneca$55
  • Boehringer Ingelheim$38
  • plus $118 from 5 others

What the payments were for

  • Food & beverage$62776%
  • Education$19824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$825 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$347,178
Medicare patients
1,704
Services billed
6,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$474,118
EntrestoSacubitril/Valsartan141$209,515
XareltoRivaroxaban50$59,238
FarxigaDapagliflozin Propanediol49$45,791
Repatha SyringeEvolocumab11$10,772
Potassium Chloride28$7,198
Metoprolol Succinate472$7,140
Atorvastatin Calcium533$5,707
Colesevelam Hcl11$5,153
Ranolazine ErRanolazine45$5,137
Rosuvastatin Calcium376$4,849
Ezetimibe108$3,537
Losartan Potassium283$2,939
Carvedilol256$2,179
Diltiazem 24hr Er (Cd)Diltiazem Hcl93$2,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$474,118368 claims
NovartisEntresto$222$209,515141 claims
Johnson & JohnsonXarelto$27$59,23850 claims
AstraZenecaFarxiga$55$45,79149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →